Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic basal cell carcinoma, however, has largely gone untested. Because PD-Ligand-1 (PD-L1) expr...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Megan Schollenberger, Evan Lipson, William H. Sharfman, Janis M. Taube, Haiying Xu, Aleksandra Ogurtsova, Jessica Esandrio, Mohammed T. Lilo, Patricia Brothers
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2017-08-01
Online Access:	https://jitc.bmj.com/content/5/1/23.full